MX2021003109A - Proteina para el tratamiento de enfermedades inflamatorias. - Google Patents

Proteina para el tratamiento de enfermedades inflamatorias.

Info

Publication number
MX2021003109A
MX2021003109A MX2021003109A MX2021003109A MX2021003109A MX 2021003109 A MX2021003109 A MX 2021003109A MX 2021003109 A MX2021003109 A MX 2021003109A MX 2021003109 A MX2021003109 A MX 2021003109A MX 2021003109 A MX2021003109 A MX 2021003109A
Authority
MX
Mexico
Prior art keywords
treatment
protein
inflammatory diseases
lectin
seq
Prior art date
Application number
MX2021003109A
Other languages
English (en)
Inventor
Dhananjay Sathe
Sudeep Kumar
Mamata Katdare
Original Assignee
Unichem Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unichem Lab Ltd filed Critical Unichem Lab Ltd
Publication of MX2021003109A publication Critical patent/MX2021003109A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4726—Lectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/178—Lectin superfamily, e.g. selectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a una lectina para su uso en el tratamiento, reducción de la progresión y curación de la inflamación en un sujeto que lo necesite. También se describen composiciones farmacéuticas que comprenden dicha lectina. La lectina puede comprender una secuencia de aminoácidos que tiene la secuencia de la SEQ ID NO: 1 o al menos 60 % de homología con la SEQ ID NO: 1.
MX2021003109A 2018-09-16 2019-09-14 Proteina para el tratamiento de enfermedades inflamatorias. MX2021003109A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201821009667 2018-09-16
PCT/IB2019/057757 WO2020074984A1 (en) 2018-09-16 2019-09-14 Protein for treatment of inflammatory diseases

Publications (1)

Publication Number Publication Date
MX2021003109A true MX2021003109A (es) 2021-05-13

Family

ID=68165661

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003109A MX2021003109A (es) 2018-09-16 2019-09-14 Proteina para el tratamiento de enfermedades inflamatorias.

Country Status (14)

Country Link
US (1) US20220047671A1 (es)
EP (1) EP3849586A1 (es)
JP (1) JP7350843B2 (es)
KR (1) KR20210058852A (es)
CN (1) CN113286604B (es)
AU (1) AU2019358599A1 (es)
BR (1) BR112021004792A2 (es)
CA (1) CA3112250A1 (es)
EA (1) EA202190310A1 (es)
MA (1) MA53614A (es)
MX (1) MX2021003109A (es)
SG (1) SG11202102501XA (es)
WO (1) WO2020074984A1 (es)
ZA (1) ZA202101587B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023524151A (ja) * 2020-05-07 2023-06-08 ユニケム ラボラトリーズ リミテッド 抗癌剤タンパク質
CN112716928B (zh) * 2021-02-22 2022-05-24 华南理工大学 辣椒素在抑制nlrp3炎症小体活化中的应用
KR20240040820A (ko) 2021-07-08 2024-03-28 유니켐 레버러토리스 리미티드 재조합 단백질, 조성물 및 이의 안정화 방법
CA3227834A1 (en) 2021-08-30 2023-03-09 Dhananjay Sathe Protein compositions for the treatment of inflammatory diseases
WO2023111892A1 (en) 2021-12-16 2023-06-22 Unichem Laboratories Limited Recombinant protein for treating sars-cov2 disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9219905D0 (en) * 1992-09-19 1992-11-04 Univ Liverpool Lectins
JPH08501569A (ja) * 1992-10-02 1996-02-20 アルバータ リサーチ カウンスル 糖質結合ペプチドの抗炎症性、免疫寛容原性、および免疫阻害性
GB9907429D0 (en) * 1999-03-31 1999-05-26 Microbiological Res Authority Modulation of C-fibre activity
WO2010050369A1 (ja) * 2008-10-31 2010-05-06 国立大学法人岡山大学 虫歯予防剤
LT3418296T (lt) * 2009-02-18 2024-10-10 Unichem Laboratories Limited Prie vėžinės ląstelės besirišantys rekombinantiniai lektinai su priešnavikiniu aktyvumu ir jų gamybos būdas
WO2014203261A2 (en) 2010-02-02 2014-12-24 Unichem Laboratories Ltd. Recombinant lectin and method of preparing thereof

Also Published As

Publication number Publication date
ZA202101587B (en) 2022-07-27
EA202190310A1 (ru) 2021-07-01
JP2022500040A (ja) 2022-01-04
CN113286604B (zh) 2023-05-12
BR112021004792A2 (pt) 2021-08-03
MA53614A (fr) 2021-07-21
US20220047671A1 (en) 2022-02-17
EP3849586A1 (en) 2021-07-21
AU2019358599A1 (en) 2021-04-22
SG11202102501XA (en) 2021-04-29
KR20210058852A (ko) 2021-05-24
CN113286604A (zh) 2021-08-20
JP7350843B2 (ja) 2023-09-26
WO2020074984A1 (en) 2020-04-16
CA3112250A1 (en) 2020-04-16

Similar Documents

Publication Publication Date Title
MX2021003109A (es) Proteina para el tratamiento de enfermedades inflamatorias.
MX2019011215A (es) Ácidos nucleicos que codifican proteínas asociadas a crispr y usos de los mismos.
PH12020550051A1 (en) Glp-1 compositions and uses thereof
EP3428182A3 (en) Anti-inflammatory peptides and composition comprising the same
EP3428181A3 (en) Anti-inflammatory peptides and composition comprising the same
PH12018502465A1 (en) Mic-1 compounds and use thereof
EA201990885A1 (ru) Композиции, содержащие короткие пептиды, полученные из pedf, и их применение
MX2019006515A (es) Composiciones que comprenden peptido wkdeagkplvk.
MX2017000378A (es) ANTICUERPOS DE UNION A PROTOFIBRILLAS BETA AMILOIDE (Aß) MEJORADOS.
MX2020009733A (es) Composiciones.
MX2019013801A (es) Compuestos de citocina inhibidora de macrofagos-1 (mic-1) y usos de estos.
MX2020008208A (es) Agentes de unión a fibroblastos y uso de estos.
WO2020123795A3 (en) Anellosomes for delivering protein replacement therapeutic modalities
MX2022005236A (es) Composiciones y metodos para el tratamiento de la perdida auditiva neurosensorial mediante el uso de sistemas de vectores duales de otoferlina.
PH12017550134A1 (en) Il-37 variants
MX2017016227A (es) Peptidos anti-infecciosos de amplio espectro.
WO2020163743A8 (en) Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems
MX2023003348A (es) Compuestos y composiciones como moduladores de señalización tlr.
PH12021550122A1 (en) Solubilized apyrases, methods and use
CR20210499A (es) Compuestos y composiciones como moduladores de la señalización de tlr
MX2020010807A (es) Peptidos promotores del crecimiento y usos de los mismos.
MX2020009566A (es) Compuestos como moduladores de la se?alizacion de tlr2.
MX2017013480A (es) Composicion farmaceutica para tratar y/o prevenir el cancer.
BR112018010225A2 (pt) peptídeos e sua utilização no tratamento do cabelo
MX2019014697A (es) Proteínas del receptor para productos finales de la glicación avanzada (rage) para el tratamiento de fibrosis y enfermedades mediadas por daño al adn.